GIC, the Singapore investment firm managing the state’s foreign reserves, has led a US$260 million (RMB1.653 billion) series B financing in CStone, a Chinese bio-pharmaceutical company.
UNLOCK DATA
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech
Want to read this important story?
Access thousands of news articles and data posts over the past 9 years!
Already have an account or paid subscription? Log in
